Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07123103) titled 'A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors' on Aug. 8.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Exelixis
Condition:
Solid Tumors
Intervention:
Drug: XB371
Recruitment Status: Recruiting
Phase: Phase 1
Date of First Enrollment: August 11, 2025
Target Sample Size: 150
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/ct2/show/NCT07123103
Published by HT Digital Content Serv...